What is the clinical evidence from this study?

Population: Doxorubicin-induced cardiotoxicity. Intervention: TC14012. Primary outcome: Cardiac function and survival rates.

What type of study is this?

This is a Animal Study study (also classified as: Quantitative Study).

October 9, 2025Circulation Research

Abstract Fri012: Dual CXCR4/CXCR7 Modulation: TC14012 as a Novel Therapeutic Strategy Against Doxorubicin-Induced Cardiotoxicity

View Full Paper

Ask AI

Bookmark

Key result

TC14012 improves cardiac function and survival in doxorubicin cardiotoxicity without compromising antitumor efficacy.

Why the study?

Does TC14012 prevent doxorubicin-induced cardiotoxicity in mice?

Key Points

TC14012 significantly improved cardiac function, enhancing ejection fraction and reducing fibrosis in mice treated with doxorubicin.
The dual modulation of CXCR4 and CXCR7 with TC14012 led to reduced inflammatory cell infiltration and improved survival rates in the studied mice.
RNA-seq analysis indicated that TC14012's cardioprotective effects are linked to enhanced AMPK signalling and metabolism in cardiac cells.
Importantly, TC14012 did not diminish doxorubicin's effectiveness against EL-4 lymphoma, suggesting a safe and effective dual-target therapy.

Structured PICO

Does TC14012 prevent doxorubicin-induced cardiotoxicity in mice?

Population

Male C57BL/6J mice receiving chronic or acute doxorubicin administration to model doxorubicin-induced cardiotoxicity.

Intervention

TC14012 (dual-target CXCR4 antagonist and CXCR7 agonist) administered twice-weekly (optimally at 5 mg/kg)

Comparator

Doxorubicin alone (implied control group)

Outcome

Cardiac function evaluated by echocardiography (ejection fraction and fractional shortening) and survival ratessurrogate

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

TC14012, a dual CXCR4/CXCR7 modulator, protects against doxorubicin-induced cardiotoxicity in mice by reprogramming cardiomyocyte metabolism and reducing mast cell activation, without reducing anticancer efficacy.

Cite This Study

Hui et al. (2025) studied Doxorubicin-induced cardiotoxicity. TC14012 was evaluated on Cardiac function and survival rates. TC14012 at 5 mg/kg significantly improved cardiac function and increased survival rates in mice with doxorubicin-induced cardiotoxicity without compromising antitumor efficacy.

synapsesocial.com/papers/68e80eb363e2e2f707877d72 https://doi.org/10.1161/res.137.suppl_1.fri012

View Full Paper

Ask AI

Bookmark

Abstract Fri012: Dual CXCR4/CXCR7 Modulation: TC14012 as a Novel Therapeutic Strategy Against Doxorubicin-Induced Cardiotoxicity

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Abstract Fri012: Dual CXCR4/CXCR7 Modulation: TC14012 as a Novel Therapeutic Strategy Against Doxorubicin-Induced Cardiotoxicity

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Keep reading

Keep reading